Please login to the form below
Microbiome
This page shows the latest Microbiome news and features for those working in and with pharma, biotech and healthcare.
Nestlé and Seres announce new partnership for C.diff microbiome therapeutic
The companies will jointly commercialise Seres’ investigational oral microbiome therapeutic in the US and Canada. ... The two companies are planning to jointly commercialise Seres’ investigational oral microbiome therapeutic SER-109 in the US and
Latest news
-
eureKARE to use $60m financing to bolster next-generation European biotech companies
New company is focused on financing biotech companies and new ventures in Europe working on the microbiome and synthetic biology. ... Dysfunction and imbalance of the microbiome is believed to be linked to up to 90% of all disease, with this field
-
Seres’ microbiome-based therapy hits the mark in phase 3
Drug reduced C.difficile infection recurrence. Seres Therapeutics has reported positive topline data from a phase 3 trail of its microbiome therapy SER-109 for recurrent C.difficile infections. ... SER-109 is an oral, biologically-derived microbiome
-
Bayer bulks up in women’s health again with non-hormonal contraceptive deal
The Evotec and Daré deals sandwiched two other agreements signed in the last few days, including a partnership with Azitra to develop skin microbiome-based treatments for eczema, and another with
-
Finch Therapeutics bags $53m for microbiome therapies
Finch’s pipeline includes CP101, an oral capsule that contains a diverse community of microbiota to restore a balanced microbiome. ... Prior studies have suggested the link between the two is a disrupted microbiome.
-
AZ signs $20m deal with Seres for microbiome project
of Seres’ microbiome candidates – SER-401 – tested in combination with AZ’s cancer therapies including its PD-L1 checkpoint inhibitor Imfinzi (durvalumab). ... One of the targets of the AZ-backed project will be to see if the microbiome can serve
eureKARE to use $60m financing to bolster next-generation European biotech companies
Seres’ microbiome-based therapy hits the mark in phase 3
Bayer bulks up in women’s health again with non-hormonal contraceptive deal
Finch Therapeutics bags $53m for microbiome therapies
AZ signs $20m deal with Seres for microbiome project
More from news
Approximately 9 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
The need for automation in healthcare
The cost-efficiency and speed of this form of testing would lend itself well to microbiome-based health tracking.
-
Gut instincts lead Takeda to GI pipeline success
Takeda’s strategy is to develop GI products that address the highest unmet needs, which includes projects across three novel platforms – gene therapy, microbiome and cell therapy.
-
A snapshot of Microbiotica
How is Microbiotica advancing life sciences with its technology? Microbiotica is a leading expert in the microbiome and is using its technology to identify the good and bad microbiomes in patients. ... There is also a $534m collaboration with Roche’s
-
Pharma’s coral reef
If you need another example, look in the mirror and consider that a large part of the creature facing you is made of other organisms, such as those in your microbiome.
-
Deal Watch November 2016
immuno-oncology collaboration based on Enterome's microbiome technology.
The need for automation in healthcare
Gut instincts lead Takeda to GI pipeline success
A snapshot of Microbiotica
Pharma’s coral reef
Deal Watch November 2016
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Former Genzyme group vice president joins Vedanta Biosciences
His experience and leadership in pioneering new drug modalities will be invaluable as we advance our pipeline of microbiome-modulating therapies.”. ... Dr Roberts said: “Microbiome modulation is among the most exciting and rapidly evolving fields in
-
Vedanta Biosciences appoints two new heads
Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.
-
Ritter Pharmaceuticals appoints new CMO
Ritter is currently developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. ... microbiome. “I believe my experience in product development coupled with my research capabilities will be a great
Former Genzyme group vice president joins Vedanta Biosciences
Vedanta Biosciences appoints two new heads
Ritter Pharmaceuticals appoints new CMO
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
5 ways that lockdowns and restrictions could be affecting our allergies
The study will initially involve characterising the profile of each infant’s gut microbiome.
-
Mastering the precision medicine opportunity
This data will come from a patient’s genetics, electronic health records, microbiome, diet, lifestyle, and will be the driving force behind improved outcomes.
5 ways that lockdowns and restrictions could be affecting our allergies
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
